Medexus Pharmaceuticals Inc. (TSE:MDP) Forecasted to Post Q1 2025 Earnings of ($0.01) Per Share

Medexus Pharmaceuticals Inc. (TSE:MDP) – Research analysts at Ventum Cap Mkts issued their Q1 2025 earnings per share estimates for shares of Medexus Pharmaceuticals in a report issued on Wednesday, June 26th. Ventum Cap Mkts analyst S. Quenneville forecasts that the company will earn ($0.01) per share for the quarter. Ventum Cap Mkts currently has a “Strong-Buy” rating on the stock. The consensus estimate for Medexus Pharmaceuticals’ current full-year earnings is $0.25 per share. Ventum Cap Mkts also issued estimates for Medexus Pharmaceuticals’ Q2 2025 earnings at $0.00 EPS, Q3 2025 earnings at $0.00 EPS, Q4 2025 earnings at $0.01 EPS and FY2025 earnings at $0.01 EPS.

Medexus Pharmaceuticals Trading Up 4.6 %

Shares of MDP opened at C$1.82 on Monday. Medexus Pharmaceuticals has a 12 month low of C$1.44 and a 12 month high of C$3.53. The stock has a fifty day moving average price of C$1.68 and a 200-day moving average price of C$1.88. The firm has a market cap of C$44.52 million, a PE ratio of 4.55 and a beta of 1.82.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.